Drug intelligence / Profile preview

lung cancer mRNA vaccine

Development stage: Preclinical
Lead developer: Hebei Bio-High Technology Development
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

The lung cancer mRNA vaccine is an investigational immunotherapy being developed by Hebei Bio-High Technology Development in partnership with Stone Pharmaceutical Group (CSPC). The vaccine utilizes mRNA technology to encode proprietary universal lung-cancer antigens, designed to stimulate a targeted immune response against lung cancer cells. The program entered a significant business development phase in July 2025 following a partnership agreement between the two companies. It is currently in the preclinical stage of development, focusing on leveraging proprietary antigens to provide a broad therapeutic effect across lung cancer patients.

Other names: 肺癌mRNA疫苗

Beyond the preview

Go deeper on lung cancer mRNA vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lung cancer mRNA vaccine.

Explore the full profile